17556 Federal Register / Vol. 72, No. 67 / Monday, April 9, 2007 / Notices 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: April 3, 2007. 

Diane Allen, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–6591 Filed 4–6–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Environmental 

Health/Agency for Toxic Substances 

and Disease Registry; The Board of 

Scientific Counselors (BSC), Centers 

for Disease Control and Prevention 

(CDC), National Center for 

Environmental Health (NCEH)/Agency 

for Toxic Substances and Disease 

Registry (ATSDR): Meeting 

In accordance with section 10(a)(2) of the 

Federal Advisory Committee Act (Pub. L. 92–

463), CDC and ATSDR announce the 

following meeting of the aforementioned 

committee: 

Times and Dates: 8 a.m.–4:45 p.m., 

May 17, 2007. 8 a.m.–12 p.m., May 18, 

2007. 

Place: 1825 Century Boulevard, 

Atlanta, Georgia 30345. 

Status: Open to the public, limited 

only by the space available. The meeting 

room accommodates approximately 75 

people. 

Purpose: The Secretary, Department 

of Health and Human Services (HHS), 

and by delegation, the Director, CDC, 

are authorized under Section 301 (42 

U.S.C. 241) and Section 311 (42 U.S.C. 

243) of the Public Health Service Act, as 

amended, to: (1) Conduct, encourage, 

cooperate with, and assist other 

appropriate public authorities, scientific 

institutions, and scientists in the 

conduct of research, investigations, 

experiments, demonstrations, and 

studies relating to the causes, diagnosis, 

treatment, control, and prevention of 

physical and mental diseases and other 

impairments; (2) assist states and their 

political subdivisions in the prevention 

of infectious diseases and other 

preventable conditions and in the 

promotion of health and well being; and 

(3) train state and local personnel in 

health work. The BSC, NCEH/ATSDR 

provides advice and guidance to the 

Secretary, HHS; the Director, CDC, and 

Administrator, ATSDR; and the 

Director, NCEH/ATSDR, regarding 

program goals, objectives, strategies, and 

priorities in fulfillment of the agency’s 

mission to protect and promote people’s 

health. The board provides advice and 

guidance that will assist NCEH/ATSDR 

in ensuring scientific quality, 

timeliness, utility, and dissemination of 

results. The board also provides 

guidance to help NCEH/ATSDR work 

more efficiently and effectively with its 

various constituents and to fulfill its 

mission in protecting America’s health. 

Matters To Be Discussed: An update 

on NCEH/ATSDR’s Office of the 

Director; an update on Science and 

Public Health and Reports; an update on 

the Health Department Subcommittee, 

the Community and Tribal 

Subcommittee, and the Program Peer 

Review Subcommittee (PPRS) Reports 

and Discussion; a presentation on CDC’s 

Web site redesign and the NCEH/ 

ATSDR Web site; an update on Climate 

Change Initiative; a presentation on the 

Office of Tribal Affairs’ Expert Panel 

Report; an update on issues from the 

Board; a discussion on the Office of 

Management and Budget Performance 

Assessment and Review Techniques 

goals and objectives; an update on the 

National Exposure Report; an update on 

Preparedness and Emergency Response 

priorities and portfolio; and a 

discussion on BSC—PPRS Draft Peer 

Review Report on ATSDR Site-Specific 

Activities. 

Agenda items are tentative and 

subject to change. 

FOR FURTHER INFORMATION CONTACT: 

Sandra Malcom, Committee 

Management Specialist, NCEH/ATSDR, 

1600 Clifton Road, Mail Stop E–28, 

Atlanta, Georgia 30303; telephone 404/ 

498–0003, fax 404/498–0622; E-mail: 

smalcom@cdc.gov. The deadline for 

notification of attendance is May 4, 

2007. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

NCEH/ATSDR. 

Dated: April 2, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–6585 Filed 4–6–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 1978N–0224 (formerly Docket 

No. 78N–0224); DESI 11853] 

Trimethobenzamide Hydrochloride 

Suppositories; Withdrawal of Approval 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

resolution of issues concerning 

trimethobenzamide hydrochloride 

suppositories. This notice announces 

the withdrawal of approval of the new 

drug application (NDA) for Tigan 

(trimethobenzamide hydrochloride) 

Suppositories. The notice also declares 

that the marketing of unapproved 

trimethobenzamide hydrochloride 

suppository products is unlawful and 

subject to FDA regulatory action. FDA is 

taking these actions because 

trimethobenzamide hydrochloride 

suppositories lack substantial evidence 

of effectiveness. 

ADDRESSES: Requests for an opinion on 

the applicability of this notice to a 

specific trimethobenzamide 

hydrochloride suppository product 

should be identified with Docket No. 

1978N–0224 and reference number DESI 

11853 and directed to the Office of 

Compliance, Division of New Drugs and 

Labeling Compliance (HFD–310), New 

Drugs and Labeling Team, Center for 

Drug Evaluation and Research, Food 

and Drug Administration, 11919 

Rockville Pike, Rockville, MD 20852. 

DATE: Effective May 9, 2007. 

FOR FURTHER INFORMATION CONTACT: 

Brian L. Pendleton, Center for Drug 

Evaluation and Research (HFD–7), Food 

and Drug Administration, 5600 Fishers 

Lane, Rockville, MD 20857, 301–594–

2041. 

SUPPLEMENTARY INFORMATION: 

I. Background 

As part of its Drug Efficacy Study 

Implementation (DESI) program, in a 

notice published in the Federal Register 

on February 24, 1971 (36 FR 3435) (the 

1971 notice), FDA announced the 

following conclusions regarding certain 

drug products that contain 

trimethobenzamide hydrochloride: (1) 

The products were probably effective for 

nausea and vomiting due to radiation 

therapy or travel sickness and for emesis 

associated with operative procedures, 

labyrinthitis, or Meniere’s syndrome; (2) 

they were lacking substantial evidence 


sroberts on PROD1PC70 with NOTICES